The miRs and target-genes validation experiments were performed in a panel of independent samples of sporadic BC (n = 9), with low risk of displaying BRCA1/2 mutation (<12%) according to Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) (http://ccge.medschl.cam.ac.uk/boadicea/). The gene discussed is BRCA1; the disease is breast cancer.